Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Immunotherapy in the First-Line Treatment of Metastatic Melanoma in Slovenia and Predictive Value of PD-L1 Expression in Tumor and Blood

NCT07422779 is registered in ClinicalTrials.gov with Institute of Oncology Ljubljana as lead sponsor.

NCT NCT07422779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07422779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Immunotherapy in the First-Line Treatment of Metastatic Melanoma in Slovenia and Predictive Value of PD-L1 Expression in Tumor and Blood
Lead sponsor
Institute of Oncology Ljubljana
Phase
Not applicable
Overall status
Recruiting
Start date
March 1, 2022
Completion date
March 31, 2028
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic melanoma, skin cancer